This monthly series highlights five large-cap, dividend-paying stocks trading at significant discounts compared to their historical norms, selected from over 7,500 U.S.-listed companies. The primary list offers an average yield of 4.2%, with two additional groups presenting moderate to high yields up to 8%. The selections aim to provide conservative dividend growth investing options with stable, long-term passive income. The author, Financially Free Investor, uses a unique approach focused on lower drawdowns, consistent income, and market-beating growth, supported by exclusive portfolios for subscribers.
The global brain implants market, valued at $7.10 billion in 2025, is projected to grow at a CAGR of 9.99% to reach $18.39 billion by 2035. Growth is fueled by advances in neurotechnology, including deep brain stimulation and brain-computer interface...
The global bloodstream infection testing market is projected to grow from $876.49 million in 2025 to $1.4 billion by 2035, at a CAGR of 4.8%. Growth is fueled by rising bloodstream infection cases, increased sepsis hospitalizations, and wider adoptio...
Abbott Laboratories shares have fallen from $127.12 to $90.53 due to sector-wide rotation and concerns over its $21 billion Exact Sciences acquisition. Despite this, its diabetes franchise, led by the FreeStyle Libre glucose monitor, and medical devi...
Abbott will announce its financial results for the second quarter of 2026 on July 16 before the market opens. The company will host a live webcast of the earnings call at 8 a.m. Central time, accessible via its Investor Relations website. Abbott is a...
Abbott Laboratories reported solid Q1 2026 results with revenue growth driven by its diversified healthcare segments, including a 13.2% rise in Medical Devices and a recent $21 billion acquisition of Exact Sciences to boost diagnostics. The company h...
